

Your pain practice manages opioid therapy every day. Your pain management MIPS score rarely shows it. Many clinics still report opioid measures CMS retired years ago. Others lose every Promoting Interoperability point on one missed attestation. The result is a final score under the 75-point performance threshold and a cut to Medicare Part B payments.
This guide lists the opioid-related measures, activities, and data completeness checks that count under current Quality Payment Program rules. Each section opens with the answer.
Pain management MIPS tracking covers four scored categories measured against a 75-point threshold. A final score of 18.75 points or lower triggers the maximum -9% payment adjustment.
CMS locked the threshold at 75 points for three performance periods, starting with this one, in the latest Physician Fee Schedule final rule. Confirm each clinician’s status in the QPP Participation Status Tool before picking measures. Our summary of current MIPS reporting requirements covers eligibility and deadlines.
Opioid-relevant MIPS quality measures still count. The trio most older guides recommend does not. Quality #408 (opioid therapy follow-up), #412 (signed opioid treatment agreement), and #414 (opioid misuse risk evaluation) left the MIPS inventory several cycles ago. They earn zero points.
These measures fit pain practices now:
| Measure | What It Measures | Potential Relevance to Pain Practices |
| Quality #468 | Continuity of pharmacotherapy for OUD | OUD treatment workflows |
| Quality #477 | Multimodal pain management for selected surgical procedures | Anesthesia and surgical pain-management workflows |
| Quality #134 | Depression screening and follow-up | Chronic pain populations with behavioral-health needs |
| Quality #305 | Initiation and engagement of SUD treatment | Practices treating or coordinating SUD care |
CMS defines opioid measures as high priority under 42 CFR 414.1305, a definition the QPP final rule fact sheet restates. The same document places Quality #477 on a flat benchmark where points start at 84% performance.
The Query of Prescription Drug Monitoring Program (PDMP) measure is a required yes/no attestation. A “No” drops the whole Promoting Interoperability category to zero, costing up to 25 points of the final score.
CMS requested feedback on a future performance-rate version of this measure. No change is final. The yes/no attestation stands.
Two improvement activities match opioid-heavy workflows. Most clinicians attest to two activities. Small practices and clinicians with other special statuses need one.
Each activity runs for at least 90 continuous days. October 3 is the last day to start a 90-day window this performance period, per the QPP small practices page. Save dated screenshots of the CDS prompt and the signed protocol. CMS data validation reviews ask for this proof.
No MIPS Value Pathway (MVP) targets interventional pain alone. Three of the 27 available MVPs overlap with pain practice work.
Multispecialty groups with more than 15 clinicians cannot register for an MVP as one group. They report as subgroups or individuals. Smaller multispecialty practices keep group registration. Traditional MIPS remains open to every eligible clinician.
Report each quality measure on at least 75% of eligible patients. A measure below that bar earns zero points outside small practices.
A monthly workflow for Quality #468 keeps the numbers clean:
Claims-based measures need a second check. Review the 835 remittance advice for every quality data code (QDC) line. A $0.00 QDC line returns remark code N620, which confirms CMS stored the code. A $0.01 line returns CO 246 with N572. A QDC line with neither code needs a template fix before more claims go out. Our guide to billing errors that hurt MIPS scores covers the denial patterns behind these gaps.
Five errors drain pain clinic MIPS scores year after year.
Substance use overlap raises its own questions. Our behavioral health MIPS reporting guide covers SUD measures in depth.
Accurate pain management MIPS tracking requires more than monitoring opioid prescribing. Your practice must report the measures that CMS currently recognizes, complete the PDMP requirement correctly, document applicable Improvement Activities, and monitor data completeness throughout the performance year.
Our reporting team audits opioid measures, PDMP attestation, and data completeness before you submit.
Book a MIPS Consultation
Can nurse practitioners in a pain clinic report these opioid measures?
Yes. Nurse practitioners, physician assistants, and certified registered nurse anesthetists are MIPS-eligible clinician types. Each must exceed the low-volume threshold, or belong to a group that exceeds it and reports as a group.
Do opioid measures earn high-priority bonus points?
No. CMS ended high-priority bonus points. An opioid measure can still fill the traditional MIPS requirement for one outcome or high-priority measure when no outcome measure fits.
Do Medicaid and commercial patients count toward data completeness?
Yes, for MIPS CQMs and eCQMs. Those collection types use all-payer data. Medicare Part B claims measures count Medicare Part B patients only.
What if our EHR cannot connect to the state PDMP?
Start with the measure exclusions. A certified EHR limitation may qualify for a Promoting Interoperability hardship exception, which reweights the category. Apply through your QPP account before the application window closes.
When does this year’s pain management MIPS score affect payment?
Two years after the performance period. CMS applies the positive, neutral, or negative adjustment to Medicare Part B physician fee schedule payments throughout that payment year.
Compliance note:
This article is educational. It is not legal, coding, or clinical advice and does not guarantee a MIPS score or payment adjustment. Confirm measure specifications in the QPP Explore Measures tool each performance period.

